Avacta’s FAP-EXd Candidate Shows Promising Preclinical Results

Avacta Group plc ( (GB:AVCT) ) has provided an update.

Avacta Group PLC announced promising preclinical results for its second pre|CISION® candidate, FAP-EXd (AVA6103), at the AACR Annual Meeting. This candidate demonstrated significant tumor growth inhibition and complete responses in therapy-resistant models, highlighting the potential of Avacta’s platform to deliver targeted cancer treatments with minimal systemic toxicity. The pre|CISION® platform targets the fibroblast activation protein (FAP) overexpressed in solid tumors, allowing for precise delivery of potent drugs like exatecan directly to the tumor site. The data presented reinforces the platform’s potential to transform cancer treatment outcomes and generate long-term value for stakeholders.

More about Avacta Group plc

Avacta Therapeutics is a clinical-stage life sciences company that focuses on developing highly potent cancer therapies using its proprietary pre|CISION® platform. This platform is based on a tumor-specific protease, fibroblast activation protein (FAP), designed to concentrate potent therapeutic agents in the tumor microenvironment while minimizing damage to normal tissues. Avacta’s pipeline includes peptide drug conjugates (PDC) and Affimer® drug conjugates (AffDC) that offer advantages over traditional antibody drug conjugates.

YTD Price Performance: -37.00%

Average Trading Volume: 1,861,978

Technical Sentiment Signal: Buy

Current Market Cap: £120.8M

See more insights into AVCT stock on TipRanks’ Stock Analysis page.